ALK's EURneffy 1 mg has received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), making it the first needle-free epinephrine rescue therapy cleared for children aged 4 and older in the 15–30 kg weight range who are at risk of severe anaphylaxis. The approval marks a meaningful extension of an intervention class — adrenaline rescue — that had previously been limited to injectable formats such as auto-injectors, repositioning the category for a population where device usability is a known clinical barrier.
EURneffy delivers a 1 mg dose of epinephrine via an intranasal route, bypassing the needle-administration step that caregivers and school staff frequently cite as a hesitation point in real-world emergency response. While the product sits outside the conventional dietary supplement or functional food channel, the approval carries direct relevance for allergy-management product developers and nutraceutical formulators building condition-specific portfolios around food-allergy support — a segment that intersects with immune health and allergy formulations. Bioavailability data supporting intranasal epinephrine delivery at therapeutic concentrations was central to the MHRA submission, with the regulator's authorisation confirming the route achieves the clinical endpoint of systemic adrenaline exposure sufficient for anaphylaxis reversal.
The pediatric food-allergy market continues to attract both pharmaceutical and nutraceutical investment. An estimated 1 in 13 children in the UK lives with a diagnosed food allergy, and the need for accessible, caregiver-friendly rescue options has driven incremental product development across both regulated and consumer-facing categories. Condition-management platforms targeting families managing peanut, tree-nut, or multi-allergen sensitivities increasingly bundle rescue preparedness guidance with daily immune-modulation supplements — a trend tracked in functional food innovation covering pediatric nutrition. Operators in that space will note that a cleared, non-injectable adrenaline option could lower the friction that currently limits school and community uptake of allergy management protocols.
ALK has not disclosed UK launch timing or volume forecasts, but the MHRA authorisation positions EURneffy 1 mg as the only product in its class for this weight band and age group, giving the company a defined first-mover window. For finished-formulation brands and co-manufacturing partners adjacent to the allergy category, the development signals continued regulatory appetite for novel delivery formats that address real-world compliance gaps — a principle equally applicable to nutraceutical dose-form innovation. This publication is part of the Food & Beverage Magazine network.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.